

# Sana M Al-Khatib

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4100677/sana-m-al-khatib-publications-by-year.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

172  
papers

5,923  
citations

36  
h-index

73  
g-index

199  
ext. papers

7,505  
ext. citations

8.9  
avg, IF

5.41  
L-index

#	Paper	IF	Citations
172	Arrhythmias in Female Patients: Incidence, Presentation and Management.. <i>Circulation Research</i> , <b>2022</b> , 130, 474-495	15.7	2
171	Feasibility of a Randomized Clinical Trial of Cardiac Resynchronization Therapy With or Without an Implantable Defibrillator in Older Patients.. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2022</b> , 101161	6.4	9
170	Outcomes of Cardiac Resynchronization Therapy with Image-Guided Left Ventricular Lead Placement at the Site of Latest Mechanical Activation: A Systematic Review and Meta-Analysis. <i>Journal of Interventional Cardiology</i> , <b>2022</b> , 2022, 1-10	1.8	0
169	Effect of Mailing Educational Material to Patients With Atrial Fibrillation and Their Clinicians on Use of Oral Anticoagulants. <i>JAMA Network Open</i> , <b>2022</b> , 5, e2214321	10.4	0
168	Sex Differences in Heart Failure. <i>Journal of Cardiac Failure</i> , <b>2021</b> ,	3.3	3
167	Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2021</b> , 14, e009614	6.4	1
166	Cardiac Resynchronization Therapy With or Without Defibrillation in Patients With Nonischemic Cardiomyopathy: A Systematic Review and Meta-Analysis. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2021</b> , 14, e008991	6.4	1
165	Emerging topics in electrophysiology. <i>Progress in Cardiovascular Diseases</i> , <b>2021</b> , 66, 1	8.5	
164	Right ventricular lead location and outcomes among patients with cardiac resynchronization therapy: A meta-analysis. <i>Progress in Cardiovascular Diseases</i> , <b>2021</b> , 66, 53-60	8.5	
163	Implantable Cardioverter Defibrillator Utilization and Mortality Among Patients $\geq$ 5 Years of Age With a Low Ejection Fraction After Coronary Revascularization. <i>American Journal of Cardiology</i> , <b>2021</b> , 138, 26-32	3	0
162	Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation. <i>Heart</i> , <b>2021</b> , 107, 713-720	5.1	5
161	Changes in the digital health landscape in cardiac electrophysiology: A pre-and peri-pandemic COVID-19 era survey.. <i>Cardiovascular Digital Health Journal</i> , <b>2021</b> , 2, 55-62	2	9
160	Response to: The paradox of implantable cardioverter-defibrillator: When guidelines play against care improvement. <i>American Heart Journal</i> , <b>2021</b> , 233, 151-152	4.9	
159	Anticoagulation after Ablation for Atrial Fibrillation. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 466-468	39.2	1
158	HRS White Paper on Clinical Utilization of Digital Health Technology.. <i>Cardiovascular Digital Health Journal</i> , <b>2021</b> , 2, 196-211	2	1
157	Sex Differences in Procedural Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion: Insights From the NCDR LAAO Registry. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 1275-1284	16.2	7
156	Outcomes for patients with anterior myocardial infarction and prior cardiac arrest in the home automated external defibrillator trial (HAT). <i>Resuscitation</i> , <b>2021</b> , 168, 75-83	4	0

155	Research Priorities in Atrial Fibrillation Screening: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop. <i>Circulation</i> , <b>2021</b> , 143, 372-388	16.7	22
154	Survey of current perspectives on consumer-available digital health devices for detecting atrial fibrillation. <i>Cardiovascular Digital Health Journal</i> , <b>2020</b> , 1, 21-29	2	10
153	Catheter ablation of atrial fibrillation in patients with diabetes mellitus. <i>Heart Rhythm O2</i> , <b>2020</b> , 1, 180-188		2
152	Advancing Research on the Complex Interrelations Between Atrial Fibrillation and Heart Failure: A Report From a US National Heart, Lung, and Blood Institute Virtual Workshop. <i>Circulation</i> , <b>2020</b> , 141, 1915-1926	16.7	20
151	Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 643-651	16.2	1
150	2019 HRS/EHRA/APHRS/LAHS expert consensus statement on catheter ablation of ventricular arrhythmias. <i>Journal of Interventional Cardiac Electrophysiology</i> , <b>2020</b> , 59, 145-298	2.4	2
149	One-year mortality after implantable cardioverter-defibrillator placement within the Veterans Affairs Health System. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 859-867	12.3	10
148	Fourth Annual Go Red for Women Issue. <i>Circulation</i> , <b>2020</b> , 141, 499-500	16.7	2
147	Future research prioritization in cardiac resynchronization therapy. <i>American Heart Journal</i> , <b>2020</b> , 223, 48-58	4.9	7
146	Research Needs and Priorities for Catheter Ablation of Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop. <i>Circulation</i> , <b>2020</b> , 141, 482-492	16.7	17
145	2019 HRS/EHRA/APHRS/LAHS expert consensus statement on catheter ablation of ventricular arrhythmias: executive summary. <i>Europace</i> , <b>2020</b> , 22, 450-495	3.9	13
144	2019 HRS/EHRA/APHRS/LAHS expert consensus statement on catheter ablation of ventricular arrhythmias: Executive summary. <i>Journal of Interventional Cardiac Electrophysiology</i> , <b>2020</b> , 59, 81-133	2.4	3
143	Sex differences in left ventricular electrical dyssynchrony and outcomes with cardiac resynchronization therapy. <i>Heart Rhythm O2</i> , <b>2020</b> , 1, 243-249	1.5	1
142	Trends in Use and In-Hospital Outcomes of Subcutaneous Implantable Cardioverter Defibrillators in Patients Undergoing Long-Term Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2020</b> , 15, 1622-1630	6.9	0
141	Sudden cardiac death in patients with myocarditis: Evaluation, risk stratification, and management. <i>American Heart Journal</i> , <b>2020</b> , 220, 29-40	4.9	20
140	Decision-making regarding primary prevention implantable cardioverter-defibrillators among older adults. <i>Clinical Cardiology</i> , <b>2020</b> , 43, 187-195	3.3	4
139	Real-world observational studies in arrhythmia research: data sources, methodology, and interpretation. A position document from European Heart Rhythm Association (EHRA), endorsed by Heart Rhythm Society (HRS), Asia-Pacific HRS (APHRS), and Latin America HRS (LAHRS). <i>Europace</i> , <b>2020</b> , 22, 831-832	3.9	14
138	Prognostic value of myocardial fibrosis on cardiac magnetic resonance imaging in patients with ischemic cardiomyopathy: A systematic review. <i>American Heart Journal</i> , <b>2020</b> , 229, 52-60	4.9	6

137	Applying patient-reported outcome methodology to capture patient-reported health data: Report from an NIH Collaboratory roundtable. <i>Healthcare</i> , <b>2020</b> , 8, 100442	1.8	2
136	Regulation Without Representation: Cardiac Device Patient Knowledge and Attitudes About the FDA Regulatory Process. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2020</b> , 13, e008561	6.4	
135	Management of Atrial Fibrillation in Older Patients by Morbidity Burden: Insights From Get With The Guidelines-Atrial Fibrillation. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e017024	6	13
134	Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the IMplementation of a randomized controlled trial to imProve treatment with oral AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AFib). <i>American Heart Journal</i> , <b>2020</b> , 229, 110-117	4.9	6
133	Stellate Ganglion Blockade: an Intervention for the Management of Ventricular Arrhythmias. <i>Current Hypertension Reports</i> , <b>2020</b> , 22, 100	4.7	5
132	Treatment of Older Patients with Atrial Fibrillation by Morbidity Burden. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , <b>2020</b> ,	4.6	4
131	2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. <i>Heart Rhythm</i> , <b>2020</b> , 17, e2-e154	6.7	80
130	2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias: Executive summary. <i>Heart Rhythm</i> , <b>2020</b> , 17, e155-e205	6.7	33
129	Complications involving the subcutaneous implantable cardioverter-defibrillator: Lessons learned from MAUDE. <i>Heart Rhythm</i> , <b>2020</b> , 17, 447-454	6.7	10
128	Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial). <i>American Journal of Cardiology</i> , <b>2019</b> , 124, 1406-1412	3	7
127	ICDs Are Still an Effective Therapy to Prevent Sudden Cardiac Death in Heart Failure. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 907-910	7.9	1
126	The subcutaneous implantable cardioverter-defibrillator in review. <i>American Heart Journal</i> , <b>2019</b> , 217, 131-139	4.9	16
125	Improved patient selection for implantable defibrillators. <i>Lancet, The</i> , <b>2019</b> , 394, 1302-1304	4.0	
124	Atrial fibrillation and kidney disease: stuck outside the CABANA. <i>Kidney International</i> , <b>2019</b> , 96, 1054-1059	5.9	
123	HRS White Paper on interoperability of data from cardiac implantable electronic devices (CIEDs). <i>Heart Rhythm</i> , <b>2019</b> , 16, e107-e127	6.7	20
122	Authors Reply. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2019</b> , 30, 1137-1138	12.7	
121	2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. <i>Europace</i> , <b>2019</b> , 21, 1143-1144	3.9	114
120	Predicting atrial fibrillation recurrence after ablation in patients with heart failure: Validity of the APPLE and CAAP-AF risk scoring systems. <i>PACE - Pacing and Clinical Electrophysiology</i> , <b>2019</b> , 42, 1440-1447	1.6	7

119	Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. <i>Circulation</i> , <b>2019</b> , 139, 2292-2300	16.7	47
118	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. <i>Circulation</i> , <b>2019</b> , 139, 863-873	16.7	8
117	Exploring patient-provider decision-making for use of anticoagulation for stroke prevention in atrial fibrillation: Results of the INFORM-AF study. <i>European Journal of Cardiovascular Nursing</i> , <b>2019</b> , 18, 280-288	3.3	8
116	Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. <i>American Heart Journal</i> , <b>2019</b> , 208, 123-131	4.9	35
115	FDA-Catalyst-Using FDA's Sentinel Initiative for large-scale pragmatic randomized trials: Approach and lessons learned during the planning phase of the first trial. <i>Clinical Trials</i> , <b>2019</b> , 16, 90-97	2.2	10
114	Stroke prevention in atrial fibrillation: Closing the gap. <i>American Heart Journal</i> , <b>2019</b> , 210, 29-38	4.9	6
113	Digoxin and Mortality in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 1063-1074	15.1	99
112	Dofetilide dose reductions and discontinuations in women compared with men. <i>Heart Rhythm</i> , <b>2018</b> , 15, 478-484	6.7	16
111	The relationship between baseline and follow-up left ventricular ejection fraction with adverse events among primary prevention ICD patients. <i>American Heart Journal</i> , <b>2018</b> , 201, 17-24	4.9	4
110	When Is It Safe Not to Reimplant an Implantable Cardioverter Defibrillator at the Time of Battery Depletion?. <i>Cardiac Electrophysiology Clinics</i> , <b>2018</b> , 10, 137-144	1.4	4
109	Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 525-532	12.3	21
108	Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry. <i>American Heart Journal</i> , <b>2018</b> , 198, 123-128	4.9	8
107	The Association of Duration of participation in get with the guidelines-resuscitation with quality of Care for in-Hospital Cardiac Arrest. <i>American Heart Journal</i> , <b>2018</b> , 204, 156-162	4.9	11
106	Centers for Medicare and Medicaid Services Decision to Reconsider Coverage Indications for ICDs: Where to Now?. <i>Circulation</i> , <b>2018</b> , 137, 317-319	16.7	0
105	How well does early-career investigators' cardiovascular outcomes research training align with funded outcomes research?. <i>American Heart Journal</i> , <b>2018</b> , 196, 163-169	4.9	3
104	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i> , <b>2018</b> , 138, e272-e321	6.7	264
103	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i> , <b>2018</b> , 138, e210-e271	16.7	173
102	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i> , <b>2018</b> , 138, e272-e321	16.7	307

101	Left Atrial Appendage Electrical Isolation for Treatment of Recurrent Atrial Fibrillation: A Meta-Analysis. <i>JACC: Clinical Electrophysiology</i> , <b>2018</b> , 4, 112-120	4.6	22
100	Training cardiovascular outcomes researchers: A survey of mentees and mentors to identify critical training gaps and needs. <i>American Heart Journal</i> , <b>2018</b> , 196, 170-177	4.9	
99	Single vs. dual chamber implantable cardioverter-defibrillators or programming of implantable cardioverter-defibrillators in patients without a bradycardia pacing indication: systematic review and meta-analysis. <i>Europace</i> , <b>2018</b> , 20, 1621-1629	3.9	15
98	Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction. <i>Heart Rhythm</i> , <b>2018</b> , 15, 651-657	6.7	64
97	Response by Friedman and Al-Khatib to Letter Regarding Article, "Ventricular Fibrillation Conversion Testing After Implantation of a Subcutaneous Implantable Cardioverter Defibrillator: Report From the National Cardiovascular Data Registry". <i>Circulation</i> , <b>2018</b> , 138, 2972-2973	16.7	1
96	Is Time From Last Hospitalization for Heart Failure to Placement of a Primary Prevention Implantable Cardioverter-Defibrillator Associated With Patient Outcomes?. <i>Circulation</i> , <b>2018</b> , 138, 2787-2797	16.7	2
95	Knowledge and Insights Vested in Us by the VEST. <i>Circulation</i> , <b>2018</b> , 138, 2735-2737	16.7	2
94	Use of Oral Anticoagulation in Eligible Patients Discharged With Heart Failure and Atrial Fibrillation. <i>Circulation: Heart Failure</i> , <b>2018</b> , 11, e005356	7.6	3
93	Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review. <i>Thrombosis and Haemostasis</i> , <b>2018</b> , 118, 2171-2187	7	96
92	Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review. <i>Annals of Internal Medicine</i> , <b>2018</b> , 169, 774-787	8	15
91	Outcomes Among Older Patients Receiving Implantable Cardioverter-Defibrillators for Secondary Prevention: From the NCDR ICD Registry. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 265-274	15.1	13
90	Prescription of Guideline-Recommended Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy Among Patients Hospitalized With Heart Failure and Varying Degrees of Renal Function. <i>American Journal of Cardiology</i> , <b>2017</b> , 119, 886-892	3	5
89	Sudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting: Results From the STICH Randomized Clinical Trial (Surgical Treatment for Ischemic Heart Failure). <i>Circulation</i> , <b>2017</b> , 135, 1136-1144	16.7	10
88	Response by Hess et al to Letter Regarding Article, "Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Program". <i>Circulation</i> , <b>2017</b> , 135, e22-e23	16.7	1
87	Temporal Trends in and Factors Associated With Use of Single- Versus Dual-Coil Implantable Cardioverter-Defibrillator Leads: Data From the NCDR ICD Registry. <i>JACC: Clinical Electrophysiology</i> , <b>2017</b> , 3, 612-619	4.6	8
86	Utilization of cardiac resynchronization therapy in eligible patients hospitalized for heart failure and its association with patient outcomes. <i>American Heart Journal</i> , <b>2017</b> , 189, 48-58	4.9	23
85	New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials. <i>American Heart Journal</i> , <b>2017</b> , 191, 21-29	4.9	24
84	Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia. <i>American Journal of Cardiology</i> , <b>2017</b> , 119, 1401-1406	4	1

83	Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 525-534	16.2	13
82	Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy: A Meta-analysis. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 685-688	16.2	54
81	Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. <i>Diabetes Care</i> , <b>2017</b> , 40, 1763-1770	14.6	46
80	Outcomes Associated With Extraction Versus Capping and Abandoning Pacing and Defibrillator Leads. <i>Circulation</i> , <b>2017</b> , 136, 1387-1395	16.7	32
79	Do Implantable Cardioverter-Defibrillators Lower the Risk of Sudden Death and Total Mortality in Patients with End-Stage Renal Disease?. <i>Current Cardiovascular Risk Reports</i> , <b>2017</b> , 11, 1	0.9	
78	Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Myocardial Infarction. <i>Circulation</i> , <b>2017</b> , 135, 38-47	16.7	11
77	Survival After Secondary Prevention Implantable Cardioverter-Defibrillator Placement: An Analysis From the NCDR ICD Registry. <i>JACC: Clinical Electrophysiology</i> , <b>2017</b> , 3, 20-28	4.6	9
76	Implantable Cardioverter Defibrillators for Nonischemic Cardiomyopathy-Reply. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 1283-1284	16.2	
75	Association Between a Prolonged PR Interval and Outcomes of Cardiac Resynchronization Therapy: A Report From the National Cardiovascular Data Registry. <i>Circulation</i> , <b>2016</b> , 134, 1617-1628	16.7	27
74	Defibrillators: Selecting the Right Device for the Right Patient. <i>Circulation</i> , <b>2016</b> , 134, 1390-1404	16.7	22
73	Acute Treatment of Patients With Supraventricular Tachycardia. <i>JAMA Cardiology</i> , <b>2016</b> , 1, 483-5	16.2	2
72	Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry@ Implantable Cardioverter-Defibrillator Registry. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9,	7.6	10
71	High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , <b>2016</b> , 171, 25-32	4.9	10
70	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. <i>Heart Rhythm</i> , <b>2016</b> , 13, e50-86	6.7	142
69	Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. <i>JAMA Cardiology</i> , <b>2016</b> , 1, 73-9	16.2	13
68	Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9, e002630	7.6	25
67	History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. <i>American Heart Journal</i> , <b>2016</b> , 175, 175-83	4.9	10
66	Association Between Hospital Process Composite Performance and Patient Outcomes After In-Hospital Cardiac Arrest Care. <i>JAMA Cardiology</i> , <b>2016</b> , 1, 37-45	16.2	36

65	Catheter ablation for ventricular tachycardia (VT) in patients with ischemic heart disease: a systematic review and a meta-analysis of randomized controlled trials. <i>Journal of Interventional Cardiac Electrophysiology</i> , <b>2016</b> , 45, 111-7	2.4	12
64	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. <i>Europace</i> , <b>2016</b> , 18, 159-83	3.9	80
63	2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i> , <b>2016</b> , 133, e506-74	16.7	142
62	Chronic obstructive pulmonary disease in patients with atrial fibrillation: Insights from the ARISTOTLE trial. <i>International Journal of Cardiology</i> , <b>2016</b> , 202, 589-94	3.2	29
61	Catheter ablation of ventricular tachycardia: Lessons learned from past clinical trials and implications for future clinical trials. <i>Heart Rhythm</i> , <b>2016</b> , 13, 1748-54	6.7	16
60	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. <i>Journal of Arrhythmia</i> , <b>2016</b> , 32, 1-28	1.5	27
59	Outcomes 1 Year After Implantable Cardioverter-Defibrillator Lead Abandonment Versus Explantation for Unused or Malfunctioning Leads: A Report from the National Cardiovascular Data Registry. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2016</b> , 9,	6.4	15
58	Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings from the Get With The Guidelines-Heart Failure Program. <i>Circulation</i> , <b>2016</b> , 134, 517-26	16.7	55
57	Primary prevention implantable cardioverter-defibrillators in older racial and ethnic minority patients. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2015</b> , 8, 145-51	6.4	10
56	Implications of ventricular arrhythmia "bursts" with normal epicardial flow, myocardial blush, and ST-segment recovery in anterior ST-elevation myocardial infarction reperfusion: a biosignature of direct myocellular injury "downstream of downstream". <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2015</b> , 4, 51-9	4.3	20
55	Complications from prophylactic replacement of cardiac implantable electronic device generators in response to United States Food and Drug Administration recall: A systematic review and meta-analysis. <i>Heart Rhythm</i> , <b>2015</b> , 12, 1558-64	6.7	4
54	Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 2433-40	27.4	38
53	Management of pace-terminated ventricular arrhythmias. <i>Cardiac Electrophysiology Clinics</i> , <b>2015</b> , 7, 497-513	5.1	13
52	Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study. <i>Nephrology Dialysis Transplantation</i> , <b>2015</b> , 30, 829-35	4.3	43
51	Future Research Prioritization: Implantable Cardioverter-Defibrillator Therapy in Older Patients. <i>Journal of General Internal Medicine</i> , <b>2015</b> , 30, 1812-20	4	9
50	Antiarrhythmic drug use in patients. <i>American Journal of Cardiology</i> , <b>2015</b> , 115, 316-22	3	18
49	Accuracy and validation of an automated electronic algorithm to identify patients with atrial fibrillation at risk for stroke. <i>American Heart Journal</i> , <b>2015</b> , 169, 39-44.e2	4.9	35
48	Comparisons of hospitalization rates among younger atrial fibrillation patients receiving different antiarrhythmic drugs. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2015</b> , 8, 292-300	5.8	7



47	Response to letter regarding article, "Rates of and factors associated with infection in 200 909 Medicare implantable cardioverter-defibrillator implants: results from the National Cardiovascular Data Registry". <i>Circulation</i> , <b>2015</b> , 131, e518	16.7	0
46	Comparative Effectiveness of CRT-D Versus Defibrillator Alone in HF Patients With Moderate-to-Severe Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 2618-2629	15.1	19
45	Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. <i>European Heart Journal</i> , <b>2015</b> , 36, 3268-75	9.5	30
44	Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention. <i>Journal of the American Heart Association</i> , <b>2015</b> , 4, e002061	6	9
43	The Food and Drug Administration and pragmatic clinical trials of marketed medical products. <i>Clinical Trials</i> , <b>2015</b> , 12, 511-9	2.2	19
42	Primary prevention implantable cardioverter defibrillators are effective in preventing overall mortality in older patients. <i>Evidence-Based Medicine</i> , <b>2015</b> , 20, 217		
41	Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2015</b> , 8, 179-86	5.8	71
40	Primary prevention implantable cardioverter-defibrillators and survival in older women. <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 159-67	7.9	26
39	Catheter ablation for ventricular tachycardia in patients with an implantable cardioverter defibrillator (CALYPSO) pilot trial. <i>Journal of Cardiovascular Electrophysiology</i> , <b>2015</b> , 26, 151-7	2.7	46
38	Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 1082-7	15.1	189
37	Survival after primary prevention implantable cardioverter-defibrillator placement among patients with chronic kidney disease. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2014</b> , 7, 793-9	6.4	31
36	Associations between anticoagulation therapy and risks of mortality and readmission among patients with heart failure and atrial fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2014</b> , 7, 670-9	5.8	3
35	Predictors of an inadequate defibrillation safety margin at ICD implantation: insights from the National Cardiovascular Data Registry. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 256-64	15.1	23
34	Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches?. <i>Journal of the American Heart Association</i> , <b>2014</b> , 3,	6	33
33	Comparison of safety of sotalol versus amiodarone in patients with atrial fibrillation and coronary artery disease. <i>American Journal of Cardiology</i> , <b>2014</b> , 114, 716-22	3	7
32	Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 1541-50	15.1	67
31	Rates of and factors associated with infection in 200 909 Medicare implantable cardioverter-defibrillator implants: results from the National Cardiovascular Data Registry. <i>Circulation</i> , <b>2014</b> , 130, 1037-43	16.7	118
30	Developing a risk model for in-hospital adverse events following implantable cardioverter-defibrillator implantation: a report from the NCDR (National Cardiovascular Data Registry). <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 788-96	15.1	28

29	Early management of atrial fibrillation to prevent cardiovascular complications. <i>European Heart Journal</i> , <b>2014</b> , 35, 1448-56	9.5	128
28	Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. <i>Blood</i> , <b>2014</b> , 124, 3692-8	2.2	124
27	Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. <i>Annals of Internal Medicine</i> , <b>2014</b> , 160, 760-73	8	113
26	Clinical effectiveness of cardiac resynchronization therapy versus medical therapy alone among patients with heart failure: analysis of the ICD Registry and ADHERE. <i>Circulation: Heart Failure</i> , <b>2014</b> , 7, 926-34	7.6	11
25	Incidence and predictors of appropriate therapies delivered by the implantable cardioverter defibrillator in patients with ischemic cardiomyopathy: a systematic review. <i>International Journal of Cardiology</i> , <b>2014</b> , 177, 990-4	3.2	13
24	Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials. <i>JACC: Heart Failure</i> , <b>2014</b> , 2, 623-9	7.9	56
23	Rates of cardiopulmonary resuscitation training in the United States. <i>JAMA Internal Medicine</i> , <b>2014</b> , 174, 194-201	11.5	89
22	Association between prophylactic implantable cardioverter-defibrillators and survival in patients with left ventricular ejection fraction between 30% and 35%. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 311, 2209-15	27.4	24
21	Adherence and persistence in the use of warfarin after hospital discharge among patients with heart failure and atrial fibrillation. <i>Journal of Cardiac Failure</i> , <b>2014</b> , 20, 23-30	3.3	17
20	Quality improvement in heart rhythm care: the path forward. <i>Journal of Interventional Cardiac Electrophysiology</i> , <b>2013</b> , 36, 145-9	2.4	4
19	Performance measures to promote quality improvement in sudden cardiac arrest prevention and treatment. <i>American Heart Journal</i> , <b>2013</b> , 165, 862-8	4.9	11
18	Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. <i>European Heart Journal</i> , <b>2013</b> , 34, 2464-71	9.5	127
17	Follow-up of patients with new cardiovascular implantable electronic devices: are expertsQ recommendations implemented in routine clinical practice?. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2013</b> , 6, 108-16	6.4	31
16	Age differences in the use of implantable cardioverter-defibrillators among older patients hospitalized with heart failure. <i>Journal of Cardiovascular Electrophysiology</i> , <b>2013</b> , 24, 664-71	2.7	8
15	Promise of factor Xa inhibition in atrial fibrillation. <i>Current Cardiology Reports</i> , <b>2012</b> , 14, 70-8	4.2	2
14	Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. <i>Lancet, The</i> , <b>2012</b> , 380, 1749-58	40	150
13	Trends in use of implantable cardioverter-defibrillator therapy among patients hospitalized for heart failure: have the previously observed sex and racial disparities changed over time?. <i>Circulation</i> , <b>2012</b> , 125, 1094-101	16.7	98
12	New directions in clinical outcomes assessment : VIth International Symposium on Interventional Electrophysiology in the Management of Cardiac Arrhythmias. <i>Journal of Interventional Cardiac Electrophysiology</i> , <b>2011</b> , 32, 221-6	2.4	

11	Remote monitoring of implantable cardioverter defibrillators versus quarterly device interrogations in clinic: results from a randomized pilot clinical trial. <i>Journal of Cardiovascular Electrophysiology</i> , <b>2010</b> , 21, 545-50	2.7	83
10	Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure) study. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 1803-10	15.1	256
9	Apixaban for reduction in stroke and other Thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. <i>American Heart Journal</i> , <b>2010</b> , 159, 331-9	4.9	345
8	Planning the Safety of Atrial Fibrillation Ablation Registry Initiative (SAFARI) as a Collaborative Pan-Stakeholder Critical Path Registry Model: a Cardiac Safety Research Consortium "Incubator" Think Tank. <i>American Heart Journal</i> , <b>2010</b> , 159, 17-24	4.9	16
7	Developing the Safety of Atrial Fibrillation Ablation Registry Initiative (SAFARI) as a collaborative pan-stakeholder critical path registry model: a Cardiac Safety Research Consortium "Incubator" Think Tank. <i>American Heart Journal</i> , <b>2010</b> , 160, 619-26	4.9	11
6	Patterns of management of atrial fibrillation complicating coronary artery bypass grafting: Results from the PProject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT-IV) Trial. <i>American Heart Journal</i> , <b>2009</b> , 158, 792-8	4.9	34
5	Patient and implanting physician factors associated with mortality and complications after implantable cardioverter-defibrillator implantation, 2002-2005. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2008</b> , 1, 240-9	6.4	82
4	Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. <i>JAMA - Journal of the American Medical Association</i> , <b>2007</b> , 298, 1517-24	27.4	191
3	Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. <i>JAMA - Journal of the American Medical Association</i> , <b>2007</b> , 298, 1525-32	27.4	278
2	A case of severe ischemia-induced QT prolongation. <i>Clinical Cardiology</i> , <b>2001</b> , 24, 750	3.3	8
1	Medicine. Placebo-controls in short-term clinical trials of hypertension. <i>Science</i> , <b>2001</b> , 292, 2013-5	33.3	27